Learning Objectives:

  1. Present the rationale and clinical utility of TCR-engineered T cell immunotherapy for solid tumors
  2. Review clinical evidence of TCR-engineered T cell immunotherapy in melanoma and synovial sarcoma
  3. Discuss current and future investigational approaches with TCR-engineered T cell immunotherapy



  1. Provide a brief overview of the epidemiology and biology of AML
  2. Discuss the association of AML driver mutations with prognosis
  3. Discuss utilization of novel prognostic models in risk stratification
Session date: 
08/13/2018 - 12:00pm to 1:00pm CDT
5841 South Maryland Avenue
MC2115 HemOnc Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Carolina Soto Chervin, MD, PhD and Anand Patel, MD